Sign up to our newsletter Subscribe
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.